Feb, 2017
Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients
JAPANESE JOURNAL OF RADIOLOGY
- Volume
- 35
- Number
- 2
- First page
- 61
- Last page
- 67
- Language
- English
- Publishing type
- Research paper (scientific journal)
- DOI
- 10.1007/s11604-016-0601-z
- Publisher
- SPRINGER
PURPOSE: This retrospective, single-center study evaluated radiofrequency (RF) ablation for pulmonary metastases of sarcoma. MATERIALS AND METHODS: Forty-six patients with sarcoma (144 pulmonary metastases) underwent 88 RF ablation sessions. Data regarding local tumor progression, efficacy, procedural adverse events (AEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), overall survival (OS), and OS-associated prognostic factors were retrospectively evaluated using univariate analyses. RESULTS: Local progression occurred in 22 of 144 tumors (15.3%). Primary and secondary efficacy rates were 83.5 and 90.0% at 1 year and 76.3 and 81.4% at 2 years, respectively. Seventy-three grade 1 AEs, 33 grade 2 AEs, and no grade ≥ 3 AEs were observed. Twenty-eight patients (60.9%) remained alive and 18 died, yielding 1-, 2-, and 3-year OS rates of 80.6, 70.1, and 47.1% (median survival time, 31.7 months). Univariate analysis revealed extrapulmonary metastasis (P = 0.005), noncurative RF ablation (P = 0.009), and a post-RF ablation disease-free interval of ≤12 months (P = 0.015) as significant negative prognostic factors. CONCLUSION: RF ablation is safe, offers good local control, and may be a viable treatment option for pulmonary metastasis of sarcoma.
- Link information
- ID information
-
- DOI : 10.1007/s11604-016-0601-z
- ISSN : 1867-1071
- eISSN : 1867-108X
- Pubmed ID : 27864664
- Web of Science ID : WOS:000394270900003